raloxifene + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Osteoporosis, Post-Menopausal
Conditions
Osteoporosis, Post-Menopausal
Trial Timeline
Mar 1, 2003 → Aug 1, 2003
NCT ID
NCT00532246About raloxifene + Placebo
raloxifene + Placebo is a approved stage product being developed by Eli Lilly for Osteoporosis, Post-Menopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00532246. Target conditions include Osteoporosis, Post-Menopausal.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00371956 | Approved | Completed |
| NCT00532246 | Approved | Completed |
| NCT00190593 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoporosis, Post-Menopausal